A monoclonal antibody approach to treat BK virus infection.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers at the University Hospital Strasbourg will enroll BK virus–positive adults and follow their clinical course and laboratory markers over time. The protocol is observational and will collect virological data, clinical outcomes, and immune-related measurements to identify antibody targets and biomarkers. Collected data and samples may be used to support the development of monoclonal antibody treatments and to select candidates for future interventional trials. No experimental therapy is administered as part of this protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* BK positive
* adult
* ok to participed to research

Exclusion Criteria:

* under guardianship
* under curatorship
* opposed to research
* deprived of liberty

Where it's running

• Service de Virologie - CHU Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Principal investigator: Samira FAFI-KREMER — University Hospital, Strasbourg, France
• Study coordinator: Anne-Sophie U GEY
• Email: anne-sophie.gey@chru-strasbourg.fr
• Phone: +33 388116684

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AIC263029 in kidney transplant recipients with BK virus infection

  This trial tests whether AIC263029 is safe and tolerable and can lower BK virus levels in adults who recently had a kidney transplant and have BK viremia, compared with placebo.

  Recruiting at 14 sites Phase 2 AiCuris Anti-infective Cures AG · Birmingham, Alabama and 13 other locations · NCT07503561

• BK virus in kidney transplant patients and donors: who carries the virus and why

  This study tests BK virus in kidney transplant recipients and their donors to see where the virus comes from and how the immune system responds.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07347769

• R-MVST cell therapy for viral infections in children and young adults

  This will try giving rapidly generated virus-specific T cells (R-MVST) to children and young adults whose weakened immune systems have recurrent or treatment-resistant infections with EBV, CMV, adenovirus, or BK virus.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06926894

• Registry for understanding BK virus in kidney transplant patients

  This study is trying to understand how the immune system responds to BK virus infections in kidney transplant patients to see how different treatments can help manage the virus and prevent complications.

  Recruiting Virginia Commonwealth University · Richmond, Virginia · NCT06538961

• Treatment of viral infections using rapidly generated T cells

  This study is testing a new treatment using specially made T cells to help patients with weakened immune systems who are struggling with serious viral infections like Epstein-Barr or cytomegalovirus.

  Recruiting Phase 1 Columbia University · New York, New York · NCT05183490

• Using donor T cells to treat cancer patients with BK and JC viruses

  This study is testing if infusions of special immune cells from donors can help cancer patients with BK or JC virus infections feel better and fight their illness.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02479698

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.